Related to CSL Negotiates Option to Pevion’s Candida Vaccine for Australia and New Zealand

• Fraunhofer CMB and iBioPharma Pocket $12M for Accelerated Manufacture of Vaccines
  
• Xcellerex, Dowpharma, Biopharm, and deltaDot Win $11M Technology Development Contract
  
• Sanofi Pasteur's Flu Vaccine Manufacturing Plant Gets FDA Nod
  
• Novartis Vaccines Institute Gets Roughly $7M to Develop Bivalent Typhoid Vaccine
  
• Medicago and Genopole to Set Up Plant in France for Influenza Vaccine Production
  
• ImmunoVaccine Technologies Collaborates with Scancell to Advance DNA Vaccine Delivery
  
• FDA Okays Vaccines for 2009 H1N1 Influenza Virus
  
• Merck & Co. to Market CSL’s Seasonal Flu Vaccine in the U.S.
  
• Novavax Taps Xcellerex to Bolster Flu Vaccine Production
  
• Genetic Tech to Distribute Rosetta’s Cancer Tests in Australia, New Zealand, and Singapore
  
• Scientists Create Insect-Cell Approach to Produce Swine Flu Vaccines
  
• ImmunoCellular Therapeutics Taps UPenn to Progress Mid-Stage Glioblastoma Candidate
  
• Plant-Based Protein Production System Developed
  
• Australian Government Commissions DSM to Build Biomanufacturing Facility
  
• GlycoVaxyn and Brigham and Women’s Win $3.4M to Develop S. aureus Vaccine
  
• Crucell Receives $110M UNICEF Contract for Quinvaxem Pediatric Vaccine
  
• Virginia Commonwealth Uni to Evaluate Prophylactic CMV Vaccination Strategies with Vical
  
• DSM to Manufacture Novacta’s C. Difficile Compound for Preclinical and Phase I Studies
  
• Crucell and J&J to Develop RSV Vaccine
  
• Emergent Wins $107M Contract to Triple Anthrax Vaccine Production